Clinical trial · Observational
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma
Diagnostic and Prognostic Markers in Low-Grade Gliomas
NCT01004523CI-TRIAL-00023120completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue and blood samples from patients with low-grade glioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| flow cytometry | Other | — | UNRESOLVED |
| fluorescence in situ hybridization | Genetic | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| loss of heterozygosity analysis | Genetic | — | UNRESOLVED |
| polymerase chain reaction | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single group
- description
- Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
- interventionNames
- Genetic: fluorescence in situ hybridization
- Genetic: loss of heterozygosity analysis
- Genetic: polymerase chain reaction
- Other: flow cytometry
- Other: immunohistochemistry staining method
Primary outcomes (5)
- measure
- Alterations in chromosomes 7, 9p, 10, 17, 19q, X, or Y as determined by FISH
- timeFrame
- baseline
- measure
- Loss of chromosomal materials in chromosomes 9p, 10, 13, 17, or 22 by PCR analysis
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
1. Paraffin-embedded tumor tissue blocks of patients enrolled in NCCTG 86-72-51 or 93-72-02 and who had the diagnosis of low-grade glioma. 2. Patients who have the diagnosis of low-grade glioma with an available paraffin- embedded tumor tissue block enrolled in prospective NCCTG and Mayo studies.
References
Publications (0)
Data not yet available
No reference posted for this study.